CD86 and cancer: Additional variants like rs2681416 in B7–2 and CTLA-4c.-1661A>G have been implicated in both cancer susceptibility and immune cell infiltration, suggesting that these polymorphisms could influence cancer risk and immune responses within the tumor microenvironment.